Breast reconstruction improves quality of life, but providers must be aware of the risks and benefits of each reconstruction approach in the setting of postmastectomy radiotherapy.
ONCOLOGY recently spoke with Ana Maria Cristina De Jesus-Acosta, MD, an assistant professor of oncology at Johns Hopkins University, about the molecular characterization and treatment of pancreatic neuroendocrine tumors.
Don S. Dizon, MD, reviews the issues that cancer survivors may encounter following diagnosis and treatment and suggests strategies that may assist in management.
Mazyar Shadman, MD, MPH, discussed the study he and colleagues are conducting to evaluate CAR T-cell therapy in high-risk patients with chronic lymphocytic leukemia.
Findings from a planned interim analysis of the Ib/II Study 111 showed that lenvatinib (Lenvima) plus pembrolizumab (Keytruda) induced a disease control rate of 94% in patients with metastatic clear cell renal cell carcinoma (RCC) who reg
ONCOLOGY recently sat down with Heather Wakelee, MD, to discuss major trends in lung cancer, such as treatment advances, updates in genetic testing, the unknown risks of vaping, and where the field is headed next.
As the treatment landscape for lung cancer continues to evolve, especially within subgroups of patients with particular mutations and molecular profiles, it can be difficult for oncologists to stay up-to-date.